MYC

[Journal of Hematology & Oncology] The role of wild-type isocitrate dehydrogenase-2 (IDH2) in AML cell survival and proliferation was tested using genetic knockdown and pharmacological inhibition in AML cells and animal models.

[Cell Biology International] OSI-027 dose-dependently reduced colon cancer cell viability through inducing the cell apoptosis and induced the apoptosis of colon cancer cells via upregulation of p53-upregulated modulator of apoptosis (PUMA).

[Cell Death & Differentiation] The mechanisms underlying MYC deubiquitination in breast cancer were not well defined. Researchers reported that OTUB1 was responsible for MYC deubiquitination.

[Clinical Cancer Research] The authors tested if inhibition of DOT1L, an epigenetic regulator of normal tissue stem/progenitor populations, would target triple-negative breast cancers stem cells.

[Acta Pharmacologica Sinica] Scientists found that cinobufotalin (CB) decreased cisplatin (DDP) resistance, migration and invasion in lung adenocarcinoma and showed that CB induced ENKUR expression by suppressing PI3K/AKT signaling to downregulate c-Jun, a negative transcription factor of ENKUR.

[Cell Death Discovery] Scientists found that the expression of the c-Myc oncogene was negatively correlated with T cell infiltration rate in osteosarcoma. Pharmacological inhibition of c-Myc with JQ-1 significantly reduced tumor burden and improved overall survival in an immunocompetent syngeneic murine model of osteosarcoma.